Search hospitals

>

Rhode Island

>

Providence

Women and Infants Hospital

Claim this profile

Providence, Rhode Island 02905

Global Leader in Ovarian Cancer

Global Leader in Fallopian Tube Cancer

Conducts research for Breast Cancer

Conducts research for Endometrial Cancer

Conducts research for Peritoneal Carcinoma

349 reported clinical trials

24 medical researchers

Photo of Women and Infants Hospital in ProvidencePhoto of Women and Infants Hospital in ProvidencePhoto of Women and Infants Hospital in Providence

Summary

Women and Infants Hospital is a medical facility located in Providence, Rhode Island. This center is recognized for care of Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Endometrial Cancer, Peritoneal Carcinoma and other specialties. Women and Infants Hospital is involved with conducting 349 clinical trials across 395 conditions. There are 24 research doctors associated with this hospital, such as Cara Mathews, MD, Katina M. Robison, William M. Sikov, and Abbot R Laptook, MD.

Area of expertise

1

Ovarian Cancer

Global Leader

Women and Infants Hospital has run 109 trials for Ovarian Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRCA1 positive
2

Fallopian Tube Cancer

Global Leader

Women and Infants Hospital has run 78 trials for Fallopian Tube Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRCA2 positive

Top PIs

Clinical Trials running at Women and Infants Hospital

Ovarian Cancer

Breast Cancer

Endometrial Cancer

Uterine Cancer

Breast cancer

Cervical Cancer

Endometrial Adenocarcinoma

Fallopian Tube Cancer

Cancer

Peritoneal Carcinoma

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Sacituzumab Tirumotecan

for Ovarian Cancer

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

LY4170156

for Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Women and Infants Hospital?

Where is Women and Infants Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Women and Infants Hospital accept?

What awards or recognition has Women and Infants Hospital received?